# A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

> **NCT02711969** · PHASE1 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 6 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Apatinib mesylate

## Key facts

- **NCT ID:** NCT02711969
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-11
- **Final completion:** 2019-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711969, "A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02711969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*